State of the art in the immunopathogenesis of psoriasis

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 3, 2007, Pages 229-242

  Teunissen, M B M ^a   Piskin, G ^a   Res, P C J M ^a   De Groot, M ^a   Picavet, D I ^a   De Rie, M A ^a   Bos, J D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dendritic cells; Psoriasis; Regulatory T cells; Skin diseases; Th17 cells

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CD4 LYMPHOCYTE COUNT; DENDRITIC CELL; DRUG PROTEIN BINDING; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KERATINOCYTE; NATURAL KILLER T CELL; NONHUMAN; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SKIN DISEASE; SKIN INFLAMMATION; TH1 CELL; TH2 CELL;

EID: 34447560158     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005;152:1098-107.
2. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70.
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
4. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13:242-4.
5. Pauls K, Schon M, Kubitza RC, Homey B, Wiesenborn A, Lehmann P et al. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001;117:569-75.
6. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-selectin on CLA+ human T cells. Blood 2006;107:1421-6.
7. Ley K and Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004;4:325-35.
8. Tietz W, Allemand Y, Borges E, von Laer D, Hallmann R, Vestweber D et al. CD4+ T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J Immunol 1998;161:963-70.
9. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.
10. Homey B, Dieu-Nosjean MC, Wiesenborn A, Massacrier C, Pin JJ, Oldham E et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32.
11. Homey B, Alenius H, Muller A, Soto H, Bowman HP, Yuan W et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8:157-65.
12. Hudak S, Hagen M, Liu Y, Catron D, Oldham E, McEvoy LM et al. Immune surveillance and effector functions of CCR10(+) skin homing T cells. J Immunol 2002;169:1189-96.
13. Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW et al. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004;295:465-73.
14. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
15. Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78.
16. Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MBM. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23. Exp Dermatol 2004;13:764-72.
17. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-6.
18. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
19. Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa. Myeloid C-type lectins in innate immunity. Nat Immunol 2006;7:1258-65.
20. Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006;6:183-95.
21. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
22. Esche C, Stellato C, Beck LA. Chemokines: key players in innate and adaptive immunity. J Invest Dermatol 2005;125:615-28.
23. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2007;127:331-41.
24. Baker BS, Ovigne JM, Powles AV, Corcoran S, Fry L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003;148:670-9.
25. Miller LS, Sorensen OE, Liu PT, Jalian HR, Eshtiaghpour D, Behmanesh BE et al. TGF-alpha regulates TLR expression and function on epidermal keratinocytes. J Immunol 2005;174:6137-43.
26. Curry JL, Qin JZ, Bonish B, Carrick R, Bacon P, Panella J et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003;127:178-86.
27. Boyman O, Conrad C, Dudli C, Kielhorn E, Nickoloff BJ, Nestle FO. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 2005;152:1211-8.
28. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 2004;13:193-222.
29. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
30. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9.
31. Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002;118:49-54.
32. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928-37.
33. Wilson SB and Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003;3:211-22.
34. Gerlini G, Hefti HP, Kleinhans M, Nickoloff BJ, Burg G, Nestle FO. CD1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol 2001;117:576-82.
35. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000;165:4076-85.
36. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003;4:1164-5.
37. Cameron AL, Kirby B, Fei W, Griffiths CE. Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 2002;294:363-9.
38. Van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA et al. Circulating V(alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-8.
39. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006;116:2094-104.
40. Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T, van Rooijen N et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006;116:2105-14.
41. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999;104:1161-4.
42. Bos JD. Psoriasis, innate immunity, and gene pools. J Am Acad Dermatol 2007;56:468-71.
43. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
44. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003;3:984-93.
45. Teunissen MBM. Langerhans cells and other skin dendritic cells. In: Bos JD, editor. Skin immune system (SIS): cutaneous immunology and clinical immunodermatology. Boca Raton: CRC Press; 2005.p.123-82.
46. Blander JM and Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006;440:808-12.
47. Van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MBM. Cutting edge: Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007;178:1986-90.
48. Wollenberg A, Kraft S, Hanau D, Bieber T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446-53.
49. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-62.
50. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
51. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43.
52. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000;13:643-55.
53. Van der Fits L, van der Wei LI, Laman JD, Prens EP, Verschuren MC. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004;122:51-60.
54. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-5.
55. Foerster J, Nolte I, Schweiger S, Ehlert C, Bruinenberg M, Spaar K et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J Invest Dermatol 2004;122:61-4.
56. Nagai T, Devergne O, Mueller TF, Perkins DL, van Seventer JM, van Seventer GA. Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 2003;171:5233-43.
57. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-9.
58. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005;125:936-44.
59. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
60. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345-50.
61. Teunissen MBM, Koomen CW, de Waal MR, Wierenga EA, Bos JD. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9.
62. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176:1908-15.
63. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
64. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87.
65. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-36.
66. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44.
67. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
68. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26.
69. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51.
70. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9.
71. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-23.
72. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40.
73. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006;15:991-1004.
74. Wang F, Lee E, Lowes MA, Haider AS, Fuentes-Duculan J, Abello MV et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 2006;126:1590-9.
75. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-9.
76. Bluestone JA and Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253-7.
77. Beissert S, Schwarz A, Schwarz T. Regulatory T cells. J Invest Dermatol 2006;126:15-24.
78. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004;172:4676-80.
79. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006;177:40-4.
80. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007;123:18-29.
81. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006;177:4488-94.
82. De Boer OJ, van der Loos CM, Teeling P, van der Wal AC, Teunissen MBM. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem 2007. In press.
83. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-73.